Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
High Expression of Ceacam19, a New Member of Carcinoembryonic Antigen Gene Family, in Patients With Breast Cancer Publisher Pubmed



Estiar MA1 ; Esmaeili R2 ; Zare AA3 ; Farahmand L2 ; Fazilaty H4 ; Zekri A5 ; Jafarbeikiravani N2 ; Majidzadeha K2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Cancer Genetics Department, Breast Cancer Research Center (BCRC), ACECR, No. 146, South Gandi St, Vanak Square, Tehran, 1517964311, Iran
  3. 3. Recombinant Proteins Department, Breast Cancer Research Center, ACECR, Tehran, Iran
  4. 4. Instituto de Neurociencias UMH-SIC, Alicante, Spain
  5. 5. Department of Medical Genetics and Molecular Biology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran

Source: Clinical and Experimental Medicine Published:2017


Abstract

Carcinoembryonic antigen (CEA) family members play important roles in malignancies and are introduced as biomarkers in different types of cancers. Among them CEACAM19 (CEAL1) gene, a new member of the CEA family, remains to be fully elucidated. The aim of this study was investigating the mRNA expression level of CEACAM19 in tumor samples of breast cancer patients compared to breast tissue of normal individuals. We evaluated the expression level of this gene in 75 breast tumors by using real-time quantitative PCR. Also, we studied the correlation between CEACAM19 expression and clinicopathological features and hormone receptors status, including estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 of patients. Out of the enrolled patients, six of them (7.9%) showed low expression, ten (13.2%) showed normal expression and 59 (77.6%) showed high expression of CEACAM19. There was a significant correlation between high expression of CEACAM19 gene in tumor samples compared to normal tissues (P = 0.039). No significant correlation was seen between clinicopathological factors and disease-free survival with mRNA levels of CEACAM19 in tumor samples, while the difference between the expression of CEACAM19 in ER/PR-positive and ER/PR-negative breast cancer patients was statistically significant (P = 0.046). In conclusion, CEACAM19 showed high expression in tumor samples compared to normal mammary tissue. In addition, CEACAM19 may represent as a novel therapeutic target in certain subgroups of breast cancer patients such as ER/PR-negative. Critical roles of CEA proteins in tumor progression may nominate them as robust potential targets for therapeutic intervention in near future. © 2016, Springer International Publishing Switzerland.
Related Docs
1. Common Molecular Markers Between Circulating Tumor Cells and Blood Exosomes in Colorectal Cancer: A Systematic and Analytical Review, Cancer Management and Research (2019)
2. Enrichment of Up-Regulated and Down-Regulated Gene Clusters Using Gene Ontology, Mirnas and Lncrnas in Colorectal Cancer, Combinatorial Chemistry and High Throughput Screening (2019)
3. Clinical Significance of Ndrg3 in Patients With Breast Cancer, Future Oncology (2017)
4. Epigenetic Regulation in Oral Squamous Cell Carcinoma Microenvironment: A Comprehensive Review, Cancers (2023)
5. Current Approaches in Identification and Isolation of Cancer Stem Cells, Journal of Cellular Physiology (2019)
Experts (# of related papers)
Reza Safdari (1)